Status:
COMPLETED
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults. Medications that increase dopamine ar...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Male and female outpatients 18-55 years of age.
- Diagnosis of ADHD, by DSM-IV by clinical evaluation by an expert clinician.
- Subjects treated for anxiety disorders and depression who are on a stable medication regimen for at least one month, and who have a disorder-specific CGI-Severity score ≤ 3 (mildly ill) and who have a score on the Hamilton-Depression and Hamilton-Anxiety rating scales below 15 (mild range).
- Exclusion Criteria
- Any clinically unstable psychiatric conditions including any history of psychosis or mania, suicidality, sociopathy, criminality, or delinquency.
- Current (last 3 months) substance use disorders (alcohol or drugs),
- Medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study including cardiovascular disease, current untreated hypertension, history of renal or hepatic impairment, or a condition that will or may require treatment with opioid analgesics.
- Clinically significant abnormal baseline laboratory LFT's, which is defined as LFT's greater than the ULN.
- Mental retardation (IQ \< 80).
- Organic brain disorders including delirium, dementia, seizures, stroke, neurosurgery, and head trauma with loss of consciousness.
- Pregnant or nursing females.
- Subjects with current adequate treatment for ADHD.
- Current treatment with medication for ADHD.
- Any other concomitant medication with primarily central nervous system activity other than specified in the protocol (a stable and effective treatment regimen of an SSRI or benzodiazepine is permitted per clinical review.)
- A Clinical Global Impression (CGI) of 7 (among the most extremely ill patients) at the screening visit is exclusionary, and any subject who presents a CGI-S of 7 at any point during the study will be removed from participation.
- Subjects presenting with a CGI-Severity score of 6 (severely ill) at two consecutive visits after week 2 will be dropped from the study (i.e. A subject with a CGI of 6 at his/her week 3 visit and at week 4 visit will be dropped from the study at the week 4 visit). Subjects who are dropped for severe or worsening symptoms after exposure to the study medication will receive free follow up care as described in the detailed protocol and protocol summary.
- Non-English speaking subjects
Exclusion
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01873729
Start Date
November 1 2013
End Date
June 1 2016
Last Update
January 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114